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Abstract
Background: The identification of causal genes from genome-wide association studies (GWAS) is the next
important step for the translation of genetic findings into biologically meaningful mechanisms of disease and
potential therapeutic targets. Using novel chromatin interaction detection techniques and allele specific assays in T
and B cell lines, we provide compelling evidence that redefines causal genes at the 6q23 locus, one of the most
important loci that confers autoimmunity risk.
Results: Although the function of disease-associated non-coding single nucleotide polymorphisms (SNPs) at 6q23
is unknown, the association is generally assigned to TNFAIP3, the closest gene. However, the DNA fragment
containing the associated SNPs interacts through chromatin looping not only with TNFAIP3, but also with IL20RA,
located 680 kb upstream. The risk allele of the most likely causal SNP, rs6927172, is correlated with both a higher
frequency of interactions and increased expression of IL20RA, along with a stronger binding of both the NFκB
transcription factor and chromatin marks characteristic of active enhancers in T-cells.
Conclusions: Our results highlight the importance of gene assignment for translating GWAS findings into
biologically meaningful mechanisms of disease and potential therapeutic targets; indeed, monoclonal antibody
therapy targeting IL-20 is effective in the treatment of rheumatoid arthritis and psoriasis, both with strong GWAS
associations to this region.
Keywords: Autoimmunity, Single nucleotide polymorphisms (SNP), Genome-wide association studies (GWAS),
Causal genes, Functional genomics, Capture Hi-C
Background
In recent years, understanding of the genetic predispos-
ition to human complex diseases has been dramatically
enhanced through the application of well-powered
genome-wide association studies (GWAS). Thousands of
genetic variants (single nucleotide polymorphisms or
SNPs) have been associated with disease [1], but the
functional role of the vast majority of these disease
variants is yet to be explored. This is due to the fact that
around 90 % lie outside known coding regions of the
genome and, therefore, their potential role in patho-
logical mechanisms is not obvious [2, 3]. There is now
strong evidence supporting a role for these non-coding
variants in transcriptional regulation as they are
enriched in cell type and stimulus-specific enhancer re-
gions [4–6], which are capable of influencing their target
genes through long-range chromosomal interactions
[7–10]. Traditionally, GWAS associated variants have
been annotated with the closest or most biologically
relevant candidate gene within arbitrarily defined dis-
tances. However, this approach has been challenged
by recent chromatin looping interaction studies showing
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that interactions between enhancers and their target genes
can occur over unexpectedly large genetic distances, often
bypassing the nearest genes [11–13].
In order to link GWAS associated variants with
disease-causing genes, we have employed a hypothesis-
free method that enables the targeted characterisation of
chromatin interactions at the genome-wide level at high
resolution. While chromosome conformation capture
studies utilising chromosome conformation capture
(3C), chromosome conformation capture-on-chip (4C)
and chromosome conformation capture carbon copy
(5C) have been successfully used to identify interactions
between regulatory elements and target genes [14–16],
regions of interest and potential targets have to be con-
sidered a priori. By contrast, Hi-C allows interrogation
of all interactions on a genome-wide scale [17], but the
approach lacks resolution. Recently, a new method that
incorporates a targeted sequence capture step into Hi-C,
Capture Hi-C (CHi-C), has been developed [13, 18–20].
The method has facilitated the identification of interac-
tions between non-coding SNPs associated with cancer
and autoimmunity with their targets [18, 19, 21].
The chromosomal region 6q23 contains several variants
associated with many autoimmune diseases. These associa-
tions have been annotated to the TNFAIP3 gene, the clos-
est most plausible causal gene within the locus, with
independent variants within the gene associated with dif-
ferent diseases. There are three distinct linkage disequilib-
rium (LD) blocks independently associated with a range of
autoimmune diseases, including rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE), celiac disease (CeD),
type 1 diabetes (T1D), inflammatory bowel disease (IBD),
psoriasis (Ps) and psoriatic arthritis (PsA) [22–29]. One re-
gion, containing SNPs associated with RA, SLE, CeD, IBD
and T1D, tagged by the rs6920220 SNP, lies a considerable
distance (>181 kb) from the TNFAIP3 gene and its
functional role has, so far, been underexplored (Fig. 1g).
The second, independent association signal, tagged by
rs7752903, and predisposing to RA, SLE and CeD, spans
around 100 kb and includes the TNFAIP3 gene (Fig. 1h).
There is evidence that a TT >A polymorphism located
within this LD block, 42 kb downstream of TNFAIP3,
alters A20 (the protein encoded by TNFAIP3) expression
through impaired delivery of NFκB to the TNFAIP3 pro-
moter [9, 30, 31]. An additional association signal, tagged
by rs610604, confers risk to Ps and PsA (Fig. 1i).
The aim of the current work was to identify causal dis-
ease genes and refine the likely causal SNPs at the auto-
immunity locus 6q23 by studying long-range chromatin
interactions using CHi-C, to validate findings using
genotype specific 3C and augment the evidence further
with cell-type and genotype specific expression quantita-
tive trait loci (eQTL) and chromatin immunoprecipitation
(ChIP) analysis. Here, we report a new causal candidate
disease gene within the 6q23 region, IL20RA, which en-
codes one of the subunits of the receptor for the pro-
inflammatory cytokine IL-20. Our results suggest that
non-coding SNPs associated with RA, SLE, CeD, IBD
and T1D alter a regulatory element of IL20RA, some
680 kb away, which acts through long-range interac-
tions with the IL20RA promoter, resulting in increased
expression of the gene.
Results
6q23 variants interact with several genes, including
IL20RA, through chromatin looping
Investigation of chromatin interactions at the 6q23 locus
was carried out as part of a larger study that included all
known risk loci for RA, JIA, PsA and T1D [21]. We se-
lected four target regions mapping to 6q23 for enrich-
ment in two different CHi-C experiments: first, the
Region Capture Hi-C targeted the LD blocks (r2 > 0.8)
for three SNPs associated with the diseases under study:
rs6920220 (RA, T1D, JIA), rs7752903 (RA) and rs610604
(Ps, PsA) (Fig. 1a–c); second, the Promoter Capture tar-
geted all known gene promoters overlapping the region
500 kb upstream and downstream of the lead disease as-
sociated SNPs (Fig. 1d and e). CHi-C libraries were gen-
erated for two cell lines: GM12878, a B-lymphoblastoid
cell line, and Jurkat, a CD4+ T-lymphoblastoid cell line.
The LD block containing the intergenic 6q23 SNP,
rs6920220, targeted in the region capture, spans 47.3 kb
(chr6:137959235–138006504) and contains seven re-
striction fragments (Fig. 1b, c and g). Of these, five
were involved in statistically significant interactions.
This intergenic region, containing SNPs associated with
multiple autoimmune diseases, demonstrated a complex
pattern of interactions, shown in Fig. 1k–n. Intriguingly,
these long-range interactions involved robust and compel-
ling interactions with both IL20RA and IFNGR1, reflecting
putative roles in regulating the expression of these genes.
There is also evidence of interactions with the long
non-coding RNAs (lncRNAs) RP11-10J5.1 and RP11-
240M16.1 downstream of the TNFAIP3 gene.
The Region Capture experiments targeting both the LD
block containing RA (rs7752903) and Ps/PsA (rs610604)
associated variants, and spanning the TNFAIP3 gene along
with its upstream and downstream regions (Fig. 1h and i),
showed interactions with a region proximal to the
rs6920220 LD block, encompassing the lncRNAs RP11-
95M15.2 (a PTPN11 pseudogene) and RP11-356I2.1, the
miRNA AL357060.1 and also an upstream region contain-
ing non-coding RNAs (Y_RNA and RP11-356I2.2)
(Fig. 1k). Finally, the Region Capture experiment detected
an interaction involving TNFAIP3 and a region contain-
ing the lncRNAs RP11-10J5.1 and RP11-240M16.1 approxi-
mately 50 kb downstream of the gene, which in turn, also
interacts with the intergenic rs6920220-tagged LD
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block. Interestingly, this region, downstream of TNFAIP3,
showed an additional long-range interaction with the
IL20RA gene (Fig. 1k).
These interactions were independently validated in
the second, separate Promoter Capture experiment
(Fig. 1d, e, l and n). Furthermore, we detected an inter-
action between the promoters of TNFAIP3 and IL20RA
that was not revealed in the Region Capture experiment,
as promoters were excluded from the Region Capture
experiment (Fig. 1l).
Importantly, we sought validation of CHi-C results by
3C-quantitative real-time polymerase chain reaction
(qPCR). Higher interaction frequencies were confirmed
for all interrogated regions, compared to adjacent non-
interacting regions (Fig. 2).
To validate our analysis method, we reanalysed our
CHi-C data using a recently developed analytical algo-
rithm, CHiCAGO (Capture HiC Analysis of Genomic
Organisation (http://biorxiv.org/content/early/2015/10/
05/028068). The pattern of chromatin loops obtained
when we applied CHiCAGO was more complex, although
it confirmed our findings (Additional file 1: Figure S1).
Additional interactions not passing the significance thresh-
old in the initial analysis were found between IL22RA2 and
Fig. 1 Long-range interactions in the 6q23 locus. Genomic co-ordinates are shown along the top of each panel and tracks are labelled a–n. a HindIII
restriction fragments. b–e Regions targeted and restriction fragments included in the Region (b, c) and Promoter (d, e) Capture experiments.
f GENCODE V17 genes. g–i 1000 Genomes SNPs in LD (r2 ≥ 0.8) with the index SNPs rs6920220, associated with RA, SLE, celiac disease,
T1D and IBD (g), rs7752903, associated with RA, SLE and celiac disease (h) and rs610604, associated with Ps and PsA (i). j Topologically
associated domains (TADs) in GM12878 cells [20]. k–n Significant interactions identified in the Region and Promoter capture experiments
in GM12878 (k, l) and Jurkat (m, n) cells. The black arrow indicates the position of the rs6927172 SNP
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the rs6920220 LD block, IL22RA2 and the RP11-10J5.1
and RP11-240M16.1 lncRNAs downstream of TNFAIP3,
IFNGR1 and the rs6920220 LD block and IFNGR1 and
TNFAIP3. Further investigations will be required to valid-
ate these interactions.
Therefore, using CHi-C and validated by 3C-qPCR, we
have confirmed that an intergenic region containing SNPs
associated with RA, T1D, SLE, CeD and IBD, tagged by
rs6920220 interacts with IL20RA, IFNGR1 and the
lncRNAs RP11-10J5.1 and RP11-240M16.1. We also con-
firmed that a second region, containing TNFAIP3 and
SNPs associated with RA, SLE, CeD, PsA and Ps, interacts
with IL20RA, and a number of lncRNAs, including RP11-
10J5.1 and RP11-240M16.1.
rs6927172 shows the most regulatory potential among all
SNPs in LD with the top GWAS signal
Although rs6920220 is associated with a host of auto-
immune diseases, its intergenic location and underexplored
functional role means no causal gene has so far been un-
equivocally assigned. We therefore focused our work on
this SNP region. The autoimmunity associated SNP
rs6920220 is in tight LD (r2 > 0.8) with eight other SNPs
(rs6933404, rs62432712, rs2327832, rs928722, rs6927172,
rs35926684, rs17264332 and rs11757201). After confirm-
ation that these SNPs are involved in long-range interac-
tions with several genes, including IL20RA, IFNGR1, and
several lncRNAs, we aimed to narrow down the most
plausible causal SNP using bioinformatics. Haploreg v4.1
was used to identify SNPs with regulatory potential
[32], showing that rs6927172 demonstrates a number
of lines of evidence to support a function in disease causal-
ity, including mapping to an enhancer in B-lymphoblastoid
cell lines, primary stimulated Th17, and T-regulatory cells
(ChromHMM chromatin state). It also maps to a region of
open chromatin, characterised by DNase hypersensitivity,
shows evidence of binding regulatory proteins and lies in a
conserved region (Table 1). Furthermore, analysis of a
a
b
c
Fig. 2 Validation of CHi-C results by 3C-qPCR in GM12878 and Jurkat cell lines. The graphs show the relative interaction frequency of (a) the 6q23
intergenic disease SNPs tagged by rs6920220, (b) the TNFAIP3 gene and (c) the IL20RA gene with their respective targets (dark grey) compared to
control, non-interacting fragments (C-, light grey). Diagrams below each graph show the approximate location of the primers for the anchor, negative
control (C-) and target (★) regions. Error bars indicate standard deviation of three biological replicates; * indicates t-test P value <0.05
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Table 1 Functional annotation of SNPs in the 6q23 intergenic LD block tagged by rs6920220 using Haploregv4.1
pos (hg19) LD (r2) Variant Ref Alt AFR freq AMR freq ASN freq EUR freq SiPhy cons Promoter
histone marks
Enhancer
histone marks
DNAse Proteins bound Motifs changed
chr6:137959235 0.89 rs6933404 T C 0.11 0.11 0.00 0.17 Blooda GIb STAT
chr6:137964697 0.88 rs62432712 A G 0.08 0.10 0.00 0.17 Pax7,RORalpha1,Vax2
chr6:137973068 0.93 rs2327832 A G 0.11 0.11 0.00 0.17 5 tissuesc GI,GI,PLCNTd 10 altered motifse
chr6:137973832 0.92 rs928722 C T 0.11 0.11 0.00 0.17 GI, PLCNT, LIVf 4 altered motifsg
chr6:137999562 0.84 rs35926684 GA G 0.14 0.12 0.00 0.18 BLDh 4 altered motifsi
chr6:138002175 1 rs6927172 C G 0.12 0.10 0.00 0.17 Yes 4 tissuesj 7 tissuesk 14 tissuesl 13 bound proteinsm 8 altered motifsn
chr6:138003822 1 rs11757201 G C 0.08 0.10 0.00 0.17 Mrg,Sp4
chr6:138005515 1 rs17264332 A G 0.12 0.10 0.00 0.17 BLDo 5 altered motifsp
chr6:138006504 1 rs6920220 G A 0.12 0.10 0.00 0.17 Hltf
The following settings were used: LD threshold, r2 ≥ 0.8; 1000G Phase 1 population for LD calculation: EUR; Source for epigenomes: ChromHMM (25-state model using 12 imputed marks); Mammalian conservation
algorithm: SiPhy-omega
aDnd41 TCellLeukemia cell line
bSmall intestine
cFetal intestine small, fetal intestine large, rectal mucosa donor 31, duodenum mucosa, small intestine, rectal mucosa donor 29, stomach mucosa, placenta, fetal muscle leg, duodenum smooth muscle, fetal stomach,
sigmoid colon, colonic mucosa, fetal adrenal gland, HepG2 hepatocellular carcinoma cell line
dFetal intestine large, fetal intestine small, placenta
eBCL, GR, HDAC2, Irf, Nanog, Pou1f1, Pou2f2, RXRA, STAT, P300
fDuodenum mucosa, fetal intestine large, fetal intestine small, placenta, rectal mucosa donor 31, small intestine, stomach mucosa, HepG2 hepatocellular carcinoma cell line
gBCL, NRSF, Smad, Whn
hPrimary monocytes from peripheral blood, primary neutrophils from peripheral blood, primary B cells from cord blood, primary T helper cells PMA-I stimulated, primary T helper 17 cells PMA-I stimulated, GM12878
lymphoblastoid cells, monocytes-CD14+ RO01746 cells
iCIZ, Foxd3, HDAC2, Nanog
jPrimary T helper naïve cells from peripheral blood, primary B cells from peripheral blood, primary natural killer cells from peripheral blood, primary hematopoietic stem cells G-CSF-mobilised female, primary
hematopoietic stem cells short-term culture, adipose nuclei, duodenum smooth muscle, colon smooth muscle, rectal mucosa donor 29, stomach mucosa, duodenum mucosa, liver
kA549 EtOH 0.02 pct lung carcinoma cell line, HeLa-S3 cervical carcinoma cell line, primary mononuclear cells from peripheral blood, primary T cells effector/memory enriched from peripheral blood, primary T cells
from cord blood, primary T regulatory cells from peripheral blood, primary T helper cells from peripheral blood, primary T helper cells PMA-I stimulated, primary T helper 17 cells PMA-I stimulated, primary T helper
memory cells from peripheral blood 1, primary T helper memory cells from peripheral blood 2, primary T CD8+ memory cells from peripheral blood, primary T helper naïve cells from peripheral blood, primary T CD8+
naïve cells from peripheral blood, primary monocytes from peripheral blood, primary B cells from cord blood, primary hematopoietic stem cells, primary hematopoietic stem cells G-CSF-mobilised male, primary
neutrophils from peripheral blood, bone marrow derived cultured mesenchymal stem cells, Dnd41 TCellLeukemia cell line, GM12878 lymphoblastoid cells, HUVEC umbilical vein endothelial primary cells, monocytes-CD14+
RO01746 primary cells, osteoblast primary cells, mesenchymal stem cell derived adipocyte cultured cells
lA549 EtOH 0.02 pct lung carcinoma cell line, HeLa-S3 cervical carcinoma cell line, primary monocytes from peripheral blood, GM12878 lymphoblastoid cells, HUVEC umbilical vein endothelial primary cells, monocytes-CD14+
RO01746 primary cells, foreskin fibroblast primary cells skin01, HSMM cell derived skeletal muscle myotubes cells, primary hematopoietic stem cells G-CSF-mobilised female, primary B cells from peripheral blood, H1 derived
mesenchymal stem cells, foreskin fibroblast primary cells skin02, foreskin keratinocyte primary cells skin02, HSMM skeletal muscle myoblasts cells
mGR (A549), ERALPHA_A (ECC-1), IRF4 (GM12878), CFOS (HUVEC), CJUN (HUVEC), GATA2 (HUVEC), CEBPB (HeLa-S3), JUND (HeLa-S3), P300 (HeLa-S3), STAT1 (HeLa-S3), MAFK (K562), STAT3 (MCF10A-Er-Src), KAP1 (U2OS)
nBCL, ERalpha-a, Ets, LXR, NFkB, RORalpha1, RXRA, STAT
oDnd41 TCellLeukemia cell line
pFoxp1, HDAC2, Hoxa10, Hoxa9, Hoxd10
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library of transcription factor binding site position weight
matrices predicts that the SNP alters the binding site of
eight transcription factors, including NFκB and BCL3 [32].
Additionally, investigation of functional annotation using
RegulomeDBVersion 1.1 assigned the highest score to
rs6927172 [33] (Additional file 1: Table S1). This evidence
suggests that rs6927172 shows the most regulatory poten-
tial of those in LD with rs6920220. In support of this, a pre-
vious study showed evidence of differential transcription
factor binding to rs6927172 alleles [34].
The risk allele of the intergenic 6q23 variant rs6927172
correlates with increased expression of IL20RA
We next focused on confirming disease causal genes by
exploring the effect of SNP genotype on gene expression
levels. However, publicly available eQTL data from dif-
ferent human tissues, including B-lymphoblastoid cell
lines (LCLs), revealed no cis-eQTLs with the disease-
associated SNPs (rs6920220, rs7752903 and rs610604) or
SNPs in LD (r2 > 0.8) with them.
Since gene expression is cell type specific, the effect of
SNPs on transcription may occur in disease-relevant cell
types only. To study the correlation between 6q23 SNP
genotypes and gene expression levels in autoimmune
relevant cell types, whole genome expression data from
CD4+ and CD8+ primary T-cells obtained from 21 indi-
viduals from the Arthritis Research UK National Reposi-
tory of Healthy Volunteers (NRHV) were interrogated.
In CD4+ T-cells, the risk allele of rs6927172 correlated
with increased expression of the IL20RA gene (Fig. 3a,
P = 0.02), supporting that the physical interaction between
them plays a functional role in the transcriptional control
of IL20RA (Fig. 1). Additionally, CD4+ T-cell whole
genome expression data were available from a cohort of
102 early undifferentiated arthritis patients collected at
baseline. To avoid confounding by clinical epiphenomena
typically seen in patients, individuals that were diagnosed
with RA after follow-up were not included in the analysis.
The correlation between rs6927172 risk alleles and in-
creased expression of IL20RA was validated in this larger
cohort (Fig. 3b, P = 0.03). No correlation was found be-
tween disease-associated SNPs (rs6927172, rs7752903 or
rs610604) and expression of the previously assumed tar-
get, TNFAIP3, or the other interacting genes, including
IFNGR1, in any of the CD4+ or CD8+ T-cell cohorts.
Whole genome expression data were also available in
primary CD19+ B-cells for the same cohort, but no
eQTLs were detected for rs6927172, rs7752903 or
rs610604, suggesting that the effect of rs6927172 on
IL20RA expression may either be T-cell type specific or
stimulation-dependent in B-cells. Therefore, the eQTL
results showing that 6q23 non-coding variants are cor-
related with IL20RA messenger RNA (mRNA) expres-
sion in CD4+ T-cells further support that IL20RA is
one of the target genes in the region, as evidenced by
the CHi-C experiment.
rs6927172 risk allele shows higher frequency of
interactions with IL20RA and IFNGR1
Having established that the non-coding 6q23 SNPs inter-
act with several genes by long-range chromatin looping,
we investigated whether the different alleles of rs6927172,
the most likely candidate regulatory SNP according to bio-
informatic analysis, interact with different affinities with
their targets. Evaluation of 3C interactions was carried out
in LCLs, as they have been genotypically well characterised
Fig. 3 eQTL effect of rs6927172 on gene expression. a Increased expression of IL20RA in primary CD4+ T-cells from 21 healthy individuals carrying
the G risk allele of rs6927172, P = 0.02. b Increased expression of IL20RA in primary CD4+ T-cells from 102 early inflammatory arthritis clinic patients
carrying the risk G allele of rs6927172, P = 0.03. The three different genotypes for the SNPs are displayed on the x-axis and gene expression levels
on the y-axis. Error bars indicate standard deviation
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as part of the HapMap Project and cells carrying the three
different genotypes for the rs6927172 variant (GM11993
CC, GM12878 CG and GM07037 GG) are readily access-
ible commercially. This experiment revealed significantly
higher interaction frequencies between both IL20RA
and IFNGR1 and the restriction fragment containing
rs6927172 in individuals carrying the risk G allele of
this SNP compared with the homozygous non-risk allele
(GG versus CC, P = 0.01; CG versus CC, P = 0.01 and GG
versus CC, P = 0.04; CG versus CC, P = 0.02, respectively)
(Fig. 4). Interaction frequencies between the fragment con-
taining rs6927172 and both fragments containing the
lncRNAs RP11-10J5.1 and RP11-240M16.1 were similar
regardless of genotype (Additional file 1: Figure S2). Simi-
larly, none of the interactions between TNFAIP3 and
targets identified in the CHi-C experiment (PTPN11
pseudogene, RP11-10J5.1, RP11-240M16.1, Y_RNA and
IL20RA) and between IL20RA and RP11-10J5.1 were influ-
enced by rs6927172 genotype (Additional file 1: Figure S3).
6q23 is one of the most important loci for RA suscep-
tibility, being the third most strongly associated region
after HLA-DRB1 and PTPN22. Although T-cells are
thought to be the most important cell type in RA patho-
genesis, synovial fibroblasts have also been shown to
play a crucial role in the perpetuation of disease [35].
Therefore, we sought to evaluate the 3D conformation
of the locus in this cell type. The preferential interaction
of the fragment containing rs6927172 and IL20RA was
confirmed by 3C-qPCR in primary human synovial fi-
broblasts (Additional file 1: Figure S4).
Hence, our experiments suggest that increased IL20RA
expression that correlates with the risk G allele of
rs6927172 may be mediated through increased ability to
bind the IL20RA gene via chromatin looping.
The risk allele of rs6927172 shows increased enrichment
of regulatory proteins
To further explore the role of rs6927172 in transcrip-
tional regulation, we evaluated enrichment of chromatin
marks of active regulatory elements to this site using
chromatin immunoprecipitation (ChIP) in LCLs. We ob-
served an enrichment of histone marks, H3K4me1 and
H3K27ac, to the region containing the SNP, compared
to a non-regulatory control region (P = 0.0001 and P =
0.0001, respectively) and to a no antibody control sam-
ple (P = 0.0001 and P = 0.0008, respectively), confirming
the bioinformatic evidence that rs6927172 is located in a
regulatory element (Additional file 1: Figure S5). We
then performed allele-specific qPCR using Taqman
probes complementary to each rs6927172 allele in Jurkat
T-cells and GM12145 B-cells, which are both heterozy-
gous for the variant, and the balance between the immu-
noprecipitated fragments with the C allele or the G
allele was determined. In Jurkat cells, the risk G allele
showed evidence of increased enrichment of both
H3K4me1 (P = 0.009) and H3K27ac (P = 0.03), compared
to the non-risk allele (Fig. 5), supporting the CD4+ spe-
cific nature of the eQTL evidence and further suggesting
that the risk allele is correlated with an increased regula-
tory activity. By contrast, in GM12145 B-cells, where no
eQTL evidence was detected/observed, the non-risk C
allele showed evidence of increased enrichment for his-
tone marks (P = 0.009 and P = 0.0001 for H3K4me1 and
H3K27ac respectively), further highlighting the cell type
specificity of transcriptional regulation (Additional file 1:
Figure S5).
The rs6927172 variant was predicted to alter the bind-
ing motif for eight transcription factors, including NFκB
and BCL3 (Table 1). Since NFκB is an important mediator
Fig. 4 Genotype-specific 3C showing preferential interaction of the disease risk G allele of rs6927172 with IL20RA (a) and IFNGR1 (b). –50 kb
restriction fragment located 50 kb upstream of the rs6927172 containing restriction fragment, rs6927172 restriction fragment containing rs6927172,
rs6920220 restriction fragment containing the top GWAS SNP in the 6q23 region, NCR non-interacting control region. Error bars indicate standard
deviation of three biological replicates
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of the immune response [36] and previous studies have
shown that the TT > A variant, which maps to the
TNFAIP3 LD block tagged by rs7752903, impairs the
binding of this transcription factor [9], we experimentally
tested whether NFκB binds rs6927172 alleles with differ-
ent affinities. We performed ChIP in Jurkat and GM12878
cell lines using antibodies for the p50 and p65 subunits of
NFκB. Estimation of the C/G ratio in the immunopreci-
pitated chromatin was performed and results showed
that, in Jurkat cells, the p65 subunit of NFκB binds with
higher affinity to the risk G allele, compared to the
non-risk C allele (P = 0.007) (Fig. 5). The SNP did not
show evidence of altered binding of NFκB in the B-
lymphoblastoid cell line.
BCL3 is a transcriptional co-activator that inhibits
the nuclear translocation of the NFκB p50 subunit in
the cytoplasm and contributes to the regulation of tran-
scription of NF-κB target genes in the nucleus [37–39].
Therefore, we also investigated binding of BCL3 to the
different alleles of rs6927172 using the same approach.
Although this transcription factor seems to be part of
the transcriptional machinery at the site of the SNP,
BCL3 binding showed no statistically significant differ-
ences between the two alleles, either in Jurkat or in
GM12878 cells.
Taken together, these results suggest that the mechanism
by which the risk allele of rs6927172 increases expression
of IL20RA may be mediated by an increased regula-
tory activity and augmented binding of the transcription
factor NFκB.
Discussion
The chromosomal region 6q23 is an important locus in
autoimmunity. It is an exemplar complex non-coding
genomic region, some distance from the nearest gene,
containing enhancer elements and implicated in multiple
diseases by GWAS, but where independent variants
associate with different conditions. To date, investigation
of the functional consequences of disease-associated alleles
have focused almost exclusively on the gene TNFAIP3.
Here we present findings from a hypothesis-free, system-
atic approach using the recently developed CHi-C method
to identify causal genes at this locus. Our experiments have
revealed that the spatial organisation of the chromatin at
this region is complex, bringing together several genes with
key roles in the immune response, including IL20RA,
IFNGR1 and TNFAIP3, alongside regulatory elements
containing SNPs associated with different autoimmune
diseases. This supports the recently proposed concept of
specialised transcription factories, where co-regulated
genes come together to share transcription factors and
regulatory elements such as enhancers [40].
Previous studies investigating the functional role of
6q23 disease variants had been restricted to the SNPs
mapping to the LD block tagged by rs7752903 spanning
the TNFAIP3 gene, associated with SLE, RA and celiac dis-
ease, showing that the TT >A variant, located downstream
of TNFAIP3, impairs that gene’s expression through chro-
matin looping and altered NFκB binding [9, 30, 31, 40].
However, the functional impact of the remaining disease-
associated SNPs at the locus, such as the intergenic
rs6920220 nominally assigned to TNFAIP3, had remained
unexplored. Our CHi-C study, supplemented by confirma-
tory 3C, eQTL and ChIP evidence, offers for the first time
a firm indication that autoimmune-associated regions in
general [21], and this region in particular, can demonstrate
complex regulatory interactions with a number of plausible
candidate genes, potentially functional lncRNA genes and,
importantly, each other. The complexity of the interactions
is magnified when considering the differences observed in
cell types (here, in B and T-cell lines and synovial fibro-
blasts). Interestingly, the rs6927172 alleles, associated with
RA, correlate with IL20RA expression levels in CD4+ T-
cells, supporting the accumulating evidence that CD4+ T-
cells are the most relevant cell type to RA [41]. Published
high resolution Hi-C data were available for GM12878 B-
lymphoblastoid cells and we observed numerous, strong
interactions between the 6q23 intergenic SNPs and
IL20RA, supporting our results [42]. In contrast, these in-
teractions with the associated intergenic region were mark-
edly decreased or non-existent in cell lines that do not
express IL20RA, such as human umbilical vein endothelial
cells (HUVEC) or chronic myeloid leukaemia (K562) cells
(Additional file 1: Figure S7), supporting a cell type
dependent regulatory role for the disease-associated en-
hancer region and IL20RA.
Chromatin looping and eQTL experiments strongly
support IL20RA as a putative causal autoimmunity gene
in 6q23. The IL20RA gene encodes the IL-20 receptor α
subunit (IL-20RA), which can form a heterodimeric
receptor with either IL-20RB to bind IL-19, IL-20 and
Fig. 5 Allele-specific ChIP in Jurkat cells, showing increased binding
of H3K4me1, H3K27ac and NFκB p65 to the risk allele of rs6927172.
Error bars indicate standard deviation of three biological replicates
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IL-24, or with IL-10RB to bind IL-26 [43]. Evidence
suggests that this family of cytokines have a pro-
inflammatory effect, and are essential in the activation
of the epithelial innate immunity [44], with expression
of IL20RA detected in whole blood, T-cells, B-cells
and monocytes [45]. Recently, interactions of IL-20
subfamily cytokines with their receptors have been
shown to be involved in the pathogenesis of RA. IL-20
and its receptors are upregulated in the synovium of RA
patients [46–50] and IL-19, IL-20 and IL-22 are able to in-
crease the proliferation of synovial cells and induce IL-6,
IL-8 and CCL2 in these cells [48, 50]. In rats, experimen-
tally induced autoimmune arthritis and collagen-induced
arthritis are attenuated by IL-19 blockade [51] and admin-
istration of soluble IL-20RA [47, 51], respectively. These
cytokines also have involvement in skin inflammation
[52]. Overexpression of Il20, Il22 or Il24 in mice leads to
the development of psoriasis-like skin lesions [53–55],
and levels of IL-19, IL-20, IL-22 and IL-24 are increased
in psoriatic skin [56–58]. Notably, SNPs mapping to the
TNFAIP3 region have been shown to be associated with
Ps and PsA, but map to a different risk haplotype, tagged
by rs610604, distinct to other autoimmune diseases
[22, 26]. Very interestingly, two recent clinical trials have
demonstrated that anti-IL-20 monoclonal antibody is
effective in the treatment of RA and psoriasis [59, 60]. Fur-
thermore, levels of IL-19, IL-20, IL-24 and IL-26 are also
elevated in serum of patients with inflammatory bowel
disease [61–64], which is associated with the intergenic
6q23 variants tagged by rs6920220 [25]. The evidence
that SNPs associated with different autoimmune diseases
interact with each other and the same genes supports a
concept that regional genetic variation, regulating simi-
lar target genes, but with mechanistic and cellular dif-
ferences, are risk factors for different diseases. This
may also suggest that blocking the IL-20 pathway might
be effective in the treatment of multiple autoimmune
diseases. Indeed, a recent study has shown that select-
ing a therapeutic target with genetic data supporting its
role could double the chance of a drug’s success in clinical
improvement [65].
Our CHi-C experiment suggested another potential
novel causal gene in the 6q23 region, IFNGR1. In
addition, targeted 3C experiments found that the inter-
action between rs6927172 and this gene is stronger
when the disease risk G allele is present. IFNGR1 en-
codes one of the subunits of the interferon gamma
(IFN-γ) receptor. This cytokine plays an important role in
autoimmunity, since it is involved in macrophage activa-
tion, enhanced MHC expression on neighbouring cells,
balancing Th1/Th2 cell differentiation, and inducing the
secretion of other pro-inflammatory cytokines [66]. Al-
though it has been shown that an increased expression of
IFNGR1 in blood is associated with RA [67], we did not
detect an effect of rs6927172 genotype on this gene’s ex-
pression levels in CD4+ and CD8+ T cells. eQTLs, though,
are context-specific [6, 68–72] and, therefore, it would be
interesting to explore whether the SNP influences IFNGR1
expression in other cell types and/or under different
stimulatory conditions.
Whereas we provide evidence of additional putative
causal genes in the 6q23 region, the TNFAIP3 gene re-
mains a strong candidate. The role of TNFAIP3 in auto-
immunity is well established. The protein encoded by
TNFAIP3, A20, is induced by tumour necrosis factor
(TNF) and inhibits NFκB activation and TNF-mediated
apoptosis [73]. Mice deficient for A20 develop severe
multiorgan inflammation [74] and tissue-specific deletion
of A20 results in different phenotypes that resembles
human autoimmune diseases such as inflammatory
polyarthritis (macrophages), SLE (dendritic cells), IBD
(intestinal epithelial cells) or psoriasis (keratinocyes) [73].
Bioinformatic analysis suggested that rs6927172 is
the most likely causal SNP in the rs6920220 LD block.
Genotype specific 3C showed increased interactions
with the IL20RA gene when the risk G allele is present
compared with the non-risk allele. By contrast, the
genotype-specific interaction was not observed for the
rs6920220 variant. However, although bioinformatic
evidence and ChIP experiments coupled with previous
evidence from electrophoretic mobility shift assays [34]
point to rs6927172 as the most likely causal SNP, the
resolution of this experiment is limited by the re-
striction enzyme used; rs6927172 is located in the
same restriction fragment as rs35926684 and both
SNPs are strongly correlated (r2 = 0.8). Therefore, although
bioinformatic evidence suggests that rs35926684 is
less likely to affect binding of regulatory proteins, the
possibility that it is the causal SNP, or that both
SNPs contribute to transcriptional regulation, cannot
be excluded.
Our study illustrates the challenges in linking associ-
ated variants to function. Associated variants can be
linked to a number of genes, dependent on which en-
hancer they are located within and the cell type under
investigation. This could explain apparent inconsisten-
cies in findings; for example, how the risk variant of
rs6927172 is associated with higher levels of active en-
hancer histone marks in Jurkat cells, but has the oppos-
ite effect in GM12878 cells. Indeed, up to 50 % of allele
specific associations with epigenetic marks of enhancer
activity (histoneQTLs) have been reported to show in-
consistent direction of effects between samples, indicat-
ing the intricacies that exist in gene regulation [75].
Nonetheless, our work reinforces previous evidence that
the nearest plausible biological candidate gene is not ne-
cessarily the causal gene. While TNFAIP3 gene involve-
ment is still implicated at the 6q23 locus, the primary
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causal gene may well be IL20RA, supported by the suc-
cess of anti-IL20 therapies in RA and Ps.
It is noteworthy that the intergenic 6q23 SNP, corre-
lated with higher frequency of interactions with IL20RA,
higher expression of IL20RA and increased enrichment
of histone marks of active enhancers and NFκB, is
located at the boundary of two topologically associated
domains (TADs) (Fig. 1g and j). TADs are genomic
regions that show high levels of interaction within the
region and little or no interaction with bordering regions
and are thought to be conserved across different cell
types and species [76, 77]. It has been shown that
boundaries between TADs can separate functionally dis-
tinct regions of the genome [78]. Intriguingly, it has
been suggested that eQTLs often occur around TAD
boundaries and preferentially associate with genes across
domains [79]. There is now evidence that disruption of
TAD boundaries can cause ectopic interactions between
regulatory non-coding DNA and gene promoters, result-
ing in pathogenic phenotypes [80]. Our CHi-C experi-
ments show long-range interactions between IL20RA and
targets located outside the TAD this gene is located, i.e.
the intergenic disease-associated SNPs, TNFAIP3 and sev-
eral lncRNAs (Fig. 1). The cell lines used in these experi-
ments (GM12878 and Jurkat) are both heterozygous for
rs6927172 and genotype-specific 3C experiments showed
that the interaction between this SNP and IL20RA occurs
preferentially when the risk allele is present (Fig. 3). It
would be interesting to explore whether this autoimmun-
ity associated variant exerts its pathogenic effect through
a disruption of the TAD boundary between IL20RA and
potential regulatory elements that would not otherwise
interact with it.
Conclusions
We provide evidence that an intergenic enhancer region
on 6q23, associated with numerous autoimmune dis-
eases and nominally assigned to TNFAIP3 although over
200 kb from the nearest gene, makes allele-specific,
regulatory contact with IL20RA, the target of an existing
drug and located 680 kb away from the associated re-
gion. Our findings show how functional evaluation of
disease risk loci can help better translate GWAS findings
into biologically meaningful mechanisms of disease and
validate existing therapeutic targets or suggest potential
new ones.
Methods
Cell culture
B-lymphoblastoid cell lines (LCL) were obtained from
the Coriell Institute for Medical Research (Additional
file 1: Table S2). Cells were grown in vented 25 cm2 cell
culture flasks containing 10–20 mL of Roswell Park
Memorial Institute medium (RPMI)-1640 + 2 mM L-
glutamine culture medium, supplemented with 15 %
fetal bovine serum (FBS). Flasks were incubated up-
right at 37 °C/5 % CO2. Cultures were regularly mon-
itored to maintain a cell density in the range of 2 ×
105–5 × 105viable cells/mL. Cells were split every two
days into fresh medium until they reached a maximum
density of 1 × 106 cells/mL.
Jurkat E6.1 human leukaemic T-lymphoblast cells were
obtained from LGC Standards. Cells were grown in
vented 25 cm2 cell culture flasks containing 10–20 mL
of RPMI-1640 + 2 mM L-glutamine, supplemented with
10 % FBS. Flasks were incubated upright at 37 °C/5 %
CO2 and the cultures regularly monitored to maintain a
cell density in the range of 3 × 105–9 × 105 viable cells/mL.
These cell lines are not listed in the in the database of
commonly misidentified cell lines maintained by ICLAC,
were authenticated using STR analysis and were tested
for mycoplasma contamination (MycoSEQ® Mycoplasma
Detection System, 4460625, Life Technologies).
Capture Hi-C
Chromatin interactions at 6q23 were scrutinised using
CHi-C as part of a larger study that included all con-
firmed risk loci for four autoimmune diseases (RA, JIA,
PsA and T1D) [21].
We tested chromatin interactions in two complemen-
tary experiments: Region Capture, which targeted regions
associated with disease [22, 27, 81–83], and Promoter
Capture, which provided independent validation by cap-
turing all gene promoters within 500 kb upstream and
downstream of lead disease-associated SNPs. Associated
regions were defined by selecting all SNPs in LD with the
lead disease-associated SNP (r2 ≥ 0.8; 1000 Genomes
phase 1 EUR samples; May 2011). For the Promoter
Capture experiment, HindIII restriction fragments
were identified within 500 bp of the transcription
start site of all genes mapping to the defined regions
(Ensembl release 75; GRCh37). A control region with well
characterised long-range interactions was also included,
HBA [84]. Capture oligos (120 bp; 25–65 % GC, <3 un-
known (N) bases) were designed using a custom Perl
script within 400 bp but as close as possible to each end
of the targeted HindIII restriction fragments.
Human T-cell (Jurkat) and B-cell (GM12878) lines
were used, since they are among the most relevant cell
types in autoimmune disease [5]. Hi-C libraries were
generated as previously described [85]. Cells of 5–6 ×
107 were grown to ~90 % confluence and cross-linked
with 2 % formaldehyde for 10 min at room temperature.
The cross-linking reaction was quenched by adding cold
1 M glycine to a final concentration of 0.125 M for
5 min at room temperature, followed by 15 min on ice.
Cells were resuspended in 50 mL ice-cold lysis buffer
(10 mM Tris–HCl pH 8, 10 mM NaCl, 0.2 % Igepal CA-
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630, protease inhibitors) and lysed on ice for 30 min,
with 2 × 10 strokes of a Dounce homogeniser. Following
lysis, the nuclei were pelleted and washed with 1.25 ×
NEB Buffer 2 then resuspended in 1.25 × NEB Buffer 2.
Hi-C libraries were digested using HindIII then prepared
as described in van Berkum et al. [86] with modifications
described in Dryden et al. [18]. Pre-Capture amplifica-
tion was performed with eight cycles of PCR on multiple
parallel reactions from Hi-C libraries immobilised on
Streptavidin beads which were pooled post-PCR and
SPRI bead purified. The final library was resuspended in
30 μL TLE (10 mM Tris pH8; 0.1 mM EDTA) and the
quality and quantity assessed by Bioanalyzer and qPCR.
Hybridisation of Agilent SureSelect custom Promoter
and Region Capture RNA bait libraries to Hi-C libraries
was carried out using Agilent SureSelectXT reagents
and protocols. Post-capture amplification was carried
out using six cycles of PCR from streptavidin beads in
multiple parallel reactions, then pooled and purified
using SPRI beads.
Two biological replicates for each of the cell lines
were prepared for each target capture. Sequencing
was performed on Illumina HiSeq 2500 generating
75 bp paired-end reads (Genomic Technologies Core
Facility in the Faculty of Life Sciences, University of
Manchester). CASAVA software (v1.8.2, Illumina) was used
to make base calls; reads failing Illumina filters were re-
moved before further analysis. Promoter Capture libraries
were each sequenced on one HiSeq lane and each Region
Capture library was sequenced on 0.5 of a HiSeq lane.
Sequences were output in FASTQ format, poor quality
reads truncated or removed as necessary, using Trim-
momatic version 0.30 [87], and subsequently mapped to
the human reference genome (GRCh37/hg19) and
filtered to remove experimental artefacts using the
Hi-C User Pipeline (HiCUP, http://www.bioinformatics.-
babraham.ac.uk/projects/hicup/). Off-target di-tags, where
neither end mapped to a targeted fragment, were removed
from the final datasets.
Di-tags separated by <20 kb were removed prior to
analysis, as 3C data have shown a very high interaction
frequency within this distance [88]. Significant interac-
tions for cis interactions within 5 Mb were determined
using the ‘High resolution analysis of cis interaction
peaks’ method described by Dryden et al. [18]. To cor-
rect for experimental biases, the interactability of each
fragment was calculated to long-range, ‘trans’ fragments,
under the assumption that those represent random,
background interactions and so should be similar in any
particular baited fragment. The resulting distribution is
bimodal consisting of stochastic noise (low trans counts)
and genuine signal (high trans counts). A truncated
negative binomial distribution was fitted to the distribu-
tion. The 5 % quantile point of the non-truncated
distribution was determined to provide the noise thresh-
old. A negative binomial regression model was fitted to
the filtered data correcting for the interactability of the
captured restriction fragment and interaction distance.
For interactions where both the target and baited region
were captured (double-baited interactions) we also
accounted for the interactability of the other end.
Interactions were considered statistically significant
after combining replicates and filtering on FDR ≤ 5 %.
Significant interactions were visualised in the WashU
Epigenome Browser [89, 90].
Chromosome conformation capture (3C)
Validation of interactions was carried out on biological
replicate 3C libraries for each of the cell lines (GM12878
and Jurkat). Libraries were prepared using the cross-
linking, digestion with HindIII and ligation steps used
for the generation of Hi-C libraries [84] but without the
biotin fill-in step. qPCR was carried out using Power
SYBR® Master Mix (Life Technologies) according to the
manufacturer’s instructions using the following cycling
conditions: 50 °C 2 min, 95 °C 10 min, followed by 40 cy-
cles of 95 °C 15 s, 60 °C 1 min. qPCR was performed in
triplicate using 50 ng of 3C library [88]. Standard curves
for each primer set used in the qPCR were generated
using tenfold serial dilutions of 3C control template
libraries, prepared by digestion and random ligation of
bacterial artificial chromosomes (BACs) (Life Technolo-
gies) spanning the region of interest with minimal overlap
(Additional file 1: Table S3). Data were normalised to a
short-range ligation product using the bait primer in com-
bination with a primer for adjacent HindIII fragments, to
control for differences in cross-linking and ligation effi-
ciencies between different cell lines. 3C primers are shown
in Additional file 1: Table S4. Statistical analysis was
performed in STATA by paired t-test. P values < 0.05
were considered statistically significant. Variance between
groups was similar (two-tailed F-test for equality of two
variances P > 0.05).
Bioinformatics
To narrow down the most plausible causal SNP among
all variants in LD with the lead GWAS SNP rs6920220,
Haploreg v4.1 was used with the following settings: LD
threshold, r2 ≥ 0.8; 1000G Phase 1 population for LD cal-
culation: EUR; Source for epigenomes: ChromHMM
(25-state model using 12 imputed marks); Mammalian
conservation algorithm: SiPhy-omega. Additionally, Reg-
ulomeDBVersion 1.1 was used.
Expression quantitative trait loci (eQTLs) analysis
Public eQTL data were interrogated using Haploreg
v4.1 [32], which examines all datasets obtained from
the GTEx analysis release V6 (http://www.gtexportal.org/
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static/datasets/gtex_analysis_v6/single_tissue_eqtl_data/
GTEx_Analysis_V6_eQTLs.tar.gz), the GEUVADIS ana-
lysis (EUR and YRI panels, http://www.ebi.ac.uk/arrayex-
press/files/E-GEUV-1/analysis_results/), the NCBI eQTL
Browser (http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/
index.cgi, lymphoblastoid cell lines [91, 92], liver [93] and
brain [94]) and eight additional studies including data
obtained from tumours [95], blood [96], lung [97],
heart [98], monocytes [4], bone [99], lymphoblastoid
cell lines [100] and brain [101].
Four whole genome gene expression datasets were
available: CD4+ and CD8+ T-cells from 21 healthy indi-
viduals of the National Repository of Healthy Volunteers
(NRHV), The University of Manchester (North West
Centre for Research Ethics Committee) (Additional
files 2, 3, 4 and 5), and CD4+ T-cells and CD19+ B-
cells from 102 early undifferentiated arthritis patients,
Newcastle University (Newcastle and North Tyneside
Local Research Ethics Committee) (Additional files 6, 7, 8
and 9). Informed consent was obtained from all partici-
pants. mRNA was isolated from sorted cell subsets, quality
and concentration assessed using the Agilent Bioanalyzer
and Nanodrop, before complementary DNA (cDNA)/
complementary RNA (cRNA) conversion using Illumina
TotalPrep RNA Amplification Kits. A total of 750 ng of
cRNA was hybridised to HumanHT-12 v4 Expression
BeadChip arrays according to the manufacturer’s protocol
before being scanned on the Illumina iScan system. Raw
expression data were exported from Illumina Genome-
Studio and analysed using the R Bioconductor package
‘limma’ [102]. Briefly, the neqc function was used for log2
transformation of the data, background correction and
quantile normalisation using control probes. Principal
component analysis was used to detect batch effects. The
cDNA/cRNA conversion produced the largest batch effect
in both cohorts and was corrected using ComBat (in R
Bioconductor package sva) (http://bioconductor.org/pack-
ages/release/bioc/html/sva.html). Genome-wide genotype
data were generated using the Illumina HumanCor-
eExomeBeadChip kit. Genotype data were aligned to the
1000 genomes reference strand, pre-phased using SHA-
PEIT2 (v2.r727 or v2.r790), before imputation using IM-
PUTE2 (v2.3.0 or v2.3.1) with the 1000 genome reference
panel (Phase 1, December 2013 or June 2014). Imputed
data were hard-called to genotypes using an INFO score
cutoff of 0.8 and posterior probability of 0.9. The effect of
the SNPs on gene expression was analysed using Matrix-
EQTL (v.2.1.0) (http://www.bios.unc.edu/research/geno-
mic_software/Matrix_eQTL/) with an additive linear
model. The errorCovariance = numeric() parameter was
set to account for possible differences in variance between
groups. SNPs within 4 Mb of a gene expression probe
were considered to be cis-eQTL, since the majority (99 %)
of interactions detected in the CHi-C experiment happened
within a 4 Mb window. P values < 0.05 were considered
statistically significant. The study (N = 102 early arthritis
patients) had 80 % power to detect a change of 0.08
log expression at 5 % significance level.
Chromatin immunoprecipitation (ChIP)
1 × 107 cells were cross-linked with 1 % formaldehyde
for 10 min at room temperature. Cells were lysed in
1 mL of ChIP lysis buffer (50 mM Tris–HCl pH8.1,
10 mM EDTA, 1 % SDS, one protease inhibitor cocktail
tablet) and chromatin sheared using a Covaris S220 with
the following conditions: target base pairs: 200–400 bp,
duty cycle: 5 % for LCL; 10 % for Jurkat cells, peak inci-
dent power: 140 Watts, cycles per burst: 200, temperature:
4 °C, time: 20–25 min.
Each immunoprecipitation (IP) was carried out in trip-
licate using LCLs obtained from HapMap individuals
(Additional file 1: Table S1). The negative control was a
no antibody control or IgG. Antibodies were available
from Abcam for NFκB p50 (ab7971), NFκBp65 (ab7970),
H3K4me1 (ab8895) and H3K27ac (ab4729) and from
Santa Cruz for BCL3 (sc-185X). To detect the relative
enrichment of regions interacting with the target protein,
qPCR of ChIP and input samples was carried out. qPCR
was performed in triplicate using SYBR green, or TaqMan
probes complementary to each allele of rs6927172
for allele-specific assays (Applied Biosystems, assay ID
C___1575580_100), on an Applied Biosystems QuantStu-
dio 12 K Flex qPCR instrument. Primers were designed
for the target SNP region, positive control region and
negative control region (Additional file 1: Table S5). Fol-
lowing qPCR, the % input for each sample was calculated
and statistical analysis of ChIP data was carried out to de-
termine significant differences in antibody binding to the
different SNP genotypes in STATA by paired t-test.
P values < 0.05 were considered statistically significant.
Variance between groups was similar (two-tailed F-test for
equality of two variances P > 0.05).
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